|

- 积分
- 0
- 威望
- 0
- 包包
- 818
|
Cell Biology and Toxicology. 1996; 12: 325-329.
Y9 g. {( J7 H4 v9 t0 z© 1996 Kluwer Academic Publishers. Printed in the Netherlands / U8 X8 C4 \7 k2 P/ D6 W! f
Cell-based therapy of acute liver failure: The extracorporeal bioartificial liver ) i* p) X+ ?$ [$ o9 k; {) \/ ] `
B. Fr6mond, A. Joly, M. Desille, J.F. Desjardins, J.P. Campion and B. C16ment
) m; \$ a' D4 i9 cDetoxication and Tissue Repair Group, Institut National de la Santd et de la Recherche Mddicale,
# }' y2 k. W# }$ S1 m2 M% E0 F% H+ ]Rennes I University School of Medicine, CHRU Pontchaillou, Rennes, France + O# g. r) B/ E* a5 O
Accepted 11 July 1996 * ]9 a2 {6 Z5 \# {; c
Keywords: acute liver failure, bioartificial liver, cell-based therapy, hepatocytes
3 Z0 g% j9 Y5 U/ o- m$ Q7 AAbstract 8 ~6 Z* S* Q. `6 d
The need for an alternative treatment to orthotopic liver transplantation for acute liver failure is a - e. G& m8 c( Y! z# k
major issue, and systems capable of temporarily providing liver functions are being actively tested. 2 f2 f. O: X3 Q
Liver assist devices based on detoxication by dialysis or hemoperfusion through various membranes
6 t- _, M# R- T( `% Jor cartridges proved to be inefficient because of their lack of metabolic function. An extracorporeal / z; r5 a% o' W3 h' j. c" z0 A
hybrid bioartificial liver might be an appropriate treatment, since it can provide liver-specific : q& F3 i& p. J+ z- |1 P9 P- B8 V
functions, maintain the patient alive, and allow spontaneous recovery of the patient's own liver or ) }2 W/ l7 X+ h
act as a bridge toward liver transplantation. Many devices have been proposed, including fiat ) Z4 M( c Z+ g0 ?
culture substrates, hollow-fiber bioreactors, or microcarriers, using xenogenic hepatocytes or 5 x; ^9 f5 x0 X6 E1 S0 K& K3 {( w& I4 J
hepatoma cell lines. Various drawbacks of these devices led us to attempt to develop a reliable
8 H; G5 }, U& y5 a* g0 K% t. lextracorporeal bioartificial liver based on alginate bead-entrapped hepatocytes. This system was / F* W7 n9 Z5 B, W1 _3 T
used successfully for the correction of the Gunn rat genetic defect, which results in lack of bilirubin " ]7 K' x5 j J7 g
conjugation. The development of this system for clinical purposes requires large yields of functional 6 q3 B$ N7 U& o: m7 y
hepatocytes. We have isolated normal porcine hepatocytes by collagenase perfusion of the liver. + V. U# {' e5 p3 J% l/ y0 q
Cells were immobilized in membrane-coated alginate gel beads, which were subsequently inoculated
$ e0 n8 s6 w' G, S+ l: hinto a bioreactor. Porcine hepatocytes expressed liver-specific functions at high levels, particularly
0 s7 b7 R: A* n% k4 y1 u( N5 }protein neosynthesis and enzymatic activities involved in detoxication and biotransformation
* q4 e- M7 `/ U5 cprocesses. In addition, hepatocytes entrapped in coated alginate beads were isolated from
4 q+ s5 v3 g$ Qimmunoglobulins. This system represents a promising tool for the design of an extracorporeal
# j( W2 s& E# l6 V) A/ J; `bioartificial liver in human beings.
/ b0 I3 l. u) L: G* sAbbreviations: ALF, acute liver failure; EBAL, extracorporeal bioartificial liver; OLT, orthotopic
0 [1 P9 B7 x, r4 ]: yliver transplantation
* Q0 }( v2 u) S5 e2 pIntroduction
! \! e4 n* c4 b) a0 H$ y9 FAcute liver failure (ALF) remains a therapeutic 8 y5 h7 D+ a2 R8 ]( n
challenge. Despite recent advances, the mor- ; ^7 D/ d$ b" _! y& B) t7 Z
tality rate is high, ranging between 70% and " R& `% ]7 j5 Z; w/ k
90%, depending on both the age and the 0 w6 {$ v- G! M, a* G0 e
etiology (Hoofnagle et al., 1995). Orthotopic
2 R( J, @2 b0 J* k5 K% yliver transplantation (OLT) is the only cur-
( \ s1 T8 x7 Irently effective treatment, but it is a major and 6 T: C }3 d! [9 V( {0 N& i' ^
costly surgical procedure which requires life- 326 7 V. q0 n& _6 P; P
long immunosuppression and is associated * K3 _+ U# L: }6 P
with a significant morbidity and mortality. # y' {5 L$ G( V8 b7 ~
Furthermore, by removing the patient's own
( ?& Z; X5 z6 s+ u# nliver, OLT prevents any opportunity of a
& q. j6 A* G+ u# {5 zspontaneous hepatic recovery. Finally, scarcity
& N& B! G( t, _6 L) z! }of liver grafts is an important limiting factor. - x4 I: S1 m" Z* c. u/ G
There is therefore a striking need for alterna-
. _% n5 _7 W( J1 z8 Ative treatments. , z [& J; R4 P9 W
The disappointing results of the first- 5 U& i6 q# {6 b" F, }' ]
generation liver assist devices based on dialysis 1 W; P6 A: J X/ o* ?
or hemoperfusion through various membranes 1 D k/ n7 \7 r
or cartridges have suggested that the restora-
: n7 `9 A, G/ H! Z1 Ption of hepatic metabolic functions is required
& X; r4 C( h8 b: Zfor efficient treatment of ALF. The best way to
/ Y; e3 W' K+ ?3 I2 h) l$ I, pkeep alive patients with ALF, and to preserve 0 Y. S0 h$ h: Z$ R, S! q4 I: P
their neurological potentialities without OLT, $ A: K' p, H4 Q4 j/ ?6 d& z
would be to treat them with a hybrid, bio- 3 P P; T% m/ x( t8 ?
artificial system capable of providing appro- - O4 E, i0 E3 [3 r( K- @0 c9 _
priate hepatic functions of synthesis, biotrans- ; i$ z2 u3 | H, v( `
formation, and detoxication. Such a system
' X) K- G. W* h, q. K1 Icould allow spontaneous liver regeneration or
$ o# p/ [6 v" U' eact as a bridge toward OLT in good conditions.
- ]6 C. i3 x' g( P1 j8 qFulminant hepatic failures from viral, toxic, or
( D* j' d+ q L# Mdrug origin would be the main indication for ; n9 f7 _' q% u" l9 l
this therapy. Other indications include primary
6 r& {1 E2 Z$ }% U3 ]7 Ononfunctioning grafts after OLT or acute de- ; P# X' j2 f: E
compensations of chronic liver insufficiency. 0 {2 Y0 A( w! C
The design of such bioartificial devices is
4 U- B$ V/ R k q( O7 M# u) vcomplex. They should contain hepatocytes, , A1 U, r# E8 N9 J- ]" B
which are highly differentiated and metaboli- / b* R( k8 c, X; k# E, O$ C9 s
cally active cells and are dependent on cell-cell
* b) E7 }8 o4 \ m7 O; iand cell-matrix interactions for their survival 4 r/ x( w z/ l% G
in vitro. Due to the scarcity of human grafts, 1 _( ]( N! b" U( U2 F% H
these hepatocytes may not be normal hepato-
9 V9 N* Y+ T9 e3 qcytes of human origin. The other sources of # Z* A- P+ a+ [/ x) b
hepatocytes include either allogenic human 3 i T2 [6 k. N9 \" r7 t
immortalized and/or transformed cell lines or 1 Y( V. o# Y6 K8 ^
xenogenic hepatocytes. In order to maintain C3 \2 U; q, l0 o) U" K
these cells functional within an optimal envir- 4 S. ]7 p3 C' K& S" U
onment for metabolic exchanges, hepatocytes
+ `+ N( v( M8 Y2 l7 w" \must be in close contact with the patient's ; W( h6 z1 w3 O' Y" N
circulation through an immumoisolating ) C7 N0 E- o3 W
hemocompatible barrier that prevents any
# V( o& k2 t0 Rinteraction with blood cells and immuno-
% h; Q% L7 P1 ]9 E3 ]8 \globulins. The extracorporeal bioartificial liver
3 ?* I3 h% }7 {- T(EBAL) must be safe for the patient. The
) D9 M1 b1 r$ J0 V9 @; xminimum number of normal hepatocytes in
. t- S5 N; M4 d( n6 Y9 Dan efficient EBAL has been estimated to repre-
7 A( _# A2 Z% _* `2 {* f9 Jsent at least 10% of the total pool of a normal & C9 j Y d2 }1 N Q
liver. Cell density should be as high as possible 2 x+ E$ a2 b; y$ q6 q& Z( ?5 I- Y5 Z
so as to obtain efficient mass transfer processes
# x1 \4 G9 O. mwithout the need for a bulky device. Finally,
4 W: |& [2 I' o' xthe clinical situation of ALF requires immedi-
3 B* f# V; \7 y9 @9 _* Yate availability of the EBAL, and manufactur-
4 k0 a3 j1 ~3 m9 U! s# A/ @. Jing, storage, and maintenance of EBALs must
0 k9 Y/ }6 c, Jmeet with industrial and economic gold stan-
6 f3 k. R6 Q U& a; vdards. v5 e0 l0 B3 M0 [
Several authors have developed bioartificial 4 A# |# P% V1 |% K
liver assist devices. Dialysis with a suspension # U) }' K, o4 s4 v0 {# K& }3 I
of hepatocytes is the simplest one. This is the
/ J8 h( U% S* Q% f4 H3 U5 k- xfirst system to have been used in a human
( S9 f2 }/ [% W, L; Ybeing (Matsumura et al., 1987). However,
; n" q; F+ _" w, T$ @4 ghepatocytes are anchorage-dependent for their 6 ^; Z0 _9 W7 s; S% @
survival and function, and such a system has a
. g$ {- L/ ]* {6 Mlimited efficacy. To ensure hepatocyte adhe- ) T! P7 q. i. ?3 C' H+ P4 t& s& `
sion, a monolayer culture can be established $ m1 j) |- O: ^7 O- \
in a bioreactor with a large internal surface.
4 E; X9 C: q' _) f& f. x. _Such a bioreactor is based either on stacked
5 r: g8 l! K/ pplates (Takahaski et al., 1992) or on hollow 6 r! C) \! v9 i g0 F/ W% X
fibers (Gerlach et al., 1994; Jauregui et al.,
7 b2 x; r" \# E( R1995). In both cases, the potential outputs of
4 }) n* {& T3 P2 D% O! g. u1 Fthese two-dimensional systems are very low,
5 s8 a! ?% r' C0 R6 R/ B" wdue to the small numbers of cells compared
* A6 ?" G; ^3 H; M; ]with the very large exchange surface. The
" o5 ?* f7 K Z ~4 Mefficiency of hollow-fiber bioreactors has been
8 J- r% w" d( z1 G/ ?$ Genhanced by seeding hepatocytes in collagen R2 B" m. G" T. G
gel matrices inside the fibers (Nyberg et al., ) G+ Z5 c$ t2 y6 S p) X
1993). Promising results have been obtained in
`9 j/ K; s1 \+ E6 Idogs with D-galactosamine-induced ALF (Sie-
d/ H5 C, P& `) u/ X9 u( Ilaff et al., 1995). However, the major draw-
, B/ \6 h1 e7 `8 Q% p y' ebacks of these hollow-fiber-based bioreactors / m8 ?) }; r3 H; Z4 u, k
are time-consuming preparation and the im-
R. ~# W; E+ Y# fpossibility of long-term preservation. These
* R1 h7 Q4 g- H& E" w! Z4 _conflict with one of the major requirements of , E: g. S- q8 l0 Z, x0 i
EBAL - the absolute need for emergency
/ w) c# J: u- c) H q' W9 Davailability.
# o/ R) d1 o" [7 I, Y4 mIn order to fulfill this requirement, the bio- : [. y7 W/ f$ n/ S" R# v0 j: H
reactor must be prepared and checked in
1 S5 b% i, B& _: I5 {8 I4 Badvance, before storage. Specifically, the most 4 P& e* R" f0 ]- r/ ^0 A
time-consuming stage, i.e., preparation and 327
* p* r- A. e* d5 e- o: `& ]0 Dimmobilization of hepatocytes, must not be ! q0 n; [( Z( J6 T
done extemporaneously prior to use. It has 9 |# A2 R( ]' @3 D, A2 V+ Z! c" g
been shown that cryopreservation of hepato- 2 o: q6 R- R& s4 o1 k
cytes is possible and safe (Chesn6 et al., 1993). - I) Y+ S: u* o" f7 n5 @; f. G
A prototype meeting this major specification - j1 H: I1 }5 {/ p2 H# D
has been designed by Demetriou and collea-
" N' S3 k( _4 f- lgues and tested in rats (Arnaout et al., 1990),
^- [0 d# c) U% Z4 Qdogs (Rozga et al., 1993), and humans 3 o# V9 U4 N% w" ^1 s$ W9 }2 @
(Demetriou et al., 1995). This system contains
# V5 z; M- W* S, \& d* ecryopreserved pig hepatocytes attached to
. }" ~, F# i7 e Jmicrocarriers. Microcarriers are inoculated ( s3 q T2 r' T0 Y9 v6 }8 r
into the extracapillary space of a microporous ( {) d1 A+ I; `0 ^. B1 U
hollow-fiber bioreactor (pore size 0.2 gm). ]* q. V* ^# M$ i
Plasma from a plasma separator flows in the
* H. N C) }) F3 T- J* \6 Nintracapillary space, filters through the mem-
) K( p5 C) Z5 K+ Fbrane pores, and interacts directly with hepa-
$ e+ B4 q' D0 t- \0 w8 xtocytes before being reinjected into the
4 F' k+ t( A6 O: r5 z& e/ Spatient's circulation. A charcoal column is " O$ Q9 i# P8 X0 N+ Y1 } I
inserted in the loop. The membrane has no ) V3 A! t- Z: R9 t$ B( a+ t5 G' C
perm-selectivity, large macromolecules includ- 5 C( `9 K- s, x V! Z& f+ s9 v0 M7 R9 `( s
ing immunoglobulins being able to permeate.
7 t. n$ l; W, c; I0 v: aEighteen patients have been treated with such a 2 o y/ q3 X' F- ?2 e8 B
device (Chen et al., 1995), either for fulminant
" t( |+ g, `& w5 R: ~9 f1 ghepatitis (group A, n = 11) or for acute decom-
4 O' m5 F; g* x' b& [pensation of chronic hepatopathy (group B, * R7 p h8 J Y& a% L7 h' ]
n = 8). In group B, only two patients underwent 2 B2 a X5 |' ?+ J/ Z
OLT; all others died. In group A, all the ' x4 D. o, E! M" v9 a' O
patients have undergone OLT, but their neuro- 4 S4 D! _3 Q) m$ Q* y/ ^9 Q
logical status improved during the EBAL treat- 9 F x- t0 E7 g3 u6 [0 ^) `
ment. However, a charcoal hemoperfusion
( A# v4 a, e U d) ~8 a* Halone may also improve the neurological status 7 e/ r) {" l* J, S! K; c/ |
of patients with ALF (O'Grady et al., 1988). A 5 d s* S+ k9 K, O; z' `7 I% P
major drawback of this system is the direct + q* T$ @9 J" S1 t
contact between human plasma and pig hepa-
+ q) A. r, X* Ztocytes. Although pig hepatocytes are less 0 ]: P8 n# Z' {6 x, k, n2 ^) L
vulnerable to the cytotoxicity of human natural 4 B0 B. F1 f" d# E/ G4 |
antibodies than other cells, particularly endo-
8 O3 [# d/ l1 a8 [* mthelial cells (Fujioka et al., 1995), this direct
/ t" Z' ?1 a! i2 U: z) Dcontact is likely to be deleterious for the
" l" v' n5 o' |$ D4 hbioreactor in some cases. Complete immuno- 8 I' @$ I$ }0 }: J7 L
isolation of xenohepatocytes appears manda- . {% B+ n) C6 Y9 M6 x9 Z
tory.
. o, A3 R8 t. F( @: q) `% j. wImmunoisolation of xenohepatocytes can be
+ R' c9 g' C. t+ K" |; V: }achieved in a different design of bioreactor that 6 G s( A& b* f; {) O
is based on hepatocytes embedded within / k# D5 U% ?3 T0 v+ b6 ^, a
hate-entrapped hepatocytes % ?; ^: d* ^4 G% C2 d' B
Figure 1. Schematic diagram of a bioreactor containing porcine
: S: [$ I6 G* P3 W" x) E! Xhepatocytes entrapped in calcium alginate beads.
. ^ U7 j! O( \! h6 Y. Y d; \3 K9 Bmicrospheres made of a semipermeable matrix
! n; w8 b9 H u1 }# i/ c5 t4 U7 f: Uof calcium alginate. We have developed an ; W3 @! N& u2 B8 N: l( a" g
EBAL based on this new concept. Plasma ) P: h- A5 s6 F" @. g& P/ E/ u
flows inside the bioreactor in direct contact
, i$ I: c+ X* f! E! b8 n! Lwith beads, without the interposition of any
( m0 G S; v# v6 Sartificial membrane, since hepatocytes have no
0 ^# K' X! `0 f) D9 l$ Bdirect contact with plasma (Figure 1). These
' b8 x! a* }5 Z6 Sbeads exhibit a very large surface-volume 1 V6 E) H+ `: R+ ?3 }
ratio. Such a system allows optimal mass
! d/ l" q3 f, J" ]- G+ t7 Jtransfer conditions, with a high cell density
1 [1 q2 W. ?, {" Y2 r(up to 107 hepatocytes/ml) and minimal dead 3 Z, B5 O" _. E: i: P2 Y' P
spaces. We have been able to demonstrate the $ s V7 ?7 i L; E6 y; ?8 ~
efficacy of this device in an experimental model 5 q; u' C ~% R! _/ C L5 ~
of impaired liver function in Gunn rats
- n- w) G5 y9 X(Fr6mond et al., 1993). The homozygous Gunn
/ N& G! [2 p$ ^- D- t/ D2 nrats possess a congenital deficiency of bilirubin
, p. v$ ~) {2 d9 M% `- e% Fconjugation. When maintained in EBAL, im- 7 U( l2 z( C0 g
mobilized normal rat hepatocytes did not ex- 328 L8 M6 P L! j: }, Z7 B
hibit any loss of viability for at least 6 h of # t. }4 N3 Y. ]* L0 ^
extracorporeal circulation. In the test group of ; M1 L H5 O3 V3 h; f' [5 R
Gunn rats, the concentration of total biliary ' ]6 i9 V R2 }. i, W( H U# B
bilirubin conjugates increased rapidly, reach-
; ?) I5 N( T3 e- g$ N8 x3 Ping more than 200 gmol/L after 3 h in some ; m/ c1 f+ `) n3 C0 v
cases, as compared with less than 1 gmol/L in 4 }! N; M' n) Q
the control group. Recently, we have designed 5 a2 ]2 v. b0 h0 s$ c- I* N( K
a similar bioreactor for experimental purposes
5 f$ D4 g% s$ h+ r9 m9 H2 Lwith large mammals and future potential clin- , q8 i/ t0 J" M7 |# G' Z
ical use (Joly et al., accepted, in press). Survi-
0 W# m% b% K8 S. O' Q( P1 n5 g/ G9 Ival, proliferation, and functions of porcine
; q, S' K( Z1 _# X" M. R/ N; ihepatocytes were evaluated in primary mono- % o6 o4 t/ e6 W& u6 K7 n/ C" X
layer culture and after embedding in alginate ; ~% d5 U9 n- Q o$ {$ w
beads that were subsequently coated with a
; ?" n9 K' ]& f2 s ~5 }; Pmembrane, produced by a transacylation reac- ( r% b& l6 U! [* ?: V
tion between alginate and albumin, in order to
4 [/ f9 z8 [8 |- ?) oimprove the immunoisolation. Disruption of w/ _, l# r o2 I6 l4 \1 F
whole pig livers by collagenase perfusion al- 5 d* J0 `2 e/ t. x6 |* M
lowed up to 8 x 101° hepatocytes, with a viabi-
& G: [, j6 f8 g0 flity greater than 90%, to be obtained.
0 [: W0 c/ x$ DHepatocytes in monolayer culture or en- 6 d8 C9 | N: ?5 |) R
trapped in coated alginate beads survived for # z% @" C: {' T. B
about 10 days, secreted proteins, and main- ; |# }9 L4 H0 z$ T' Q) t, r
tained at high levels several phase I and phase
6 ]- A& y) Y; V" i9 n, D wII enzymatic activities, namely, ethoxy- 8 H- U3 v: {8 A. B8 t+ z0 D4 d2 e' t
resorufin-O-deethylase, oxidation of nifedipin & C6 ?( V! g m! |' b" x! z0 T
to pyridine, phenacetin deethylation to
7 q3 k# K- V* y kparacetamol, glucuroconjugation of paraceta-
, V- E- b2 \ r) ?mol, and N-acetylation of procainamide. Typi-
) `& Y) `/ W- B6 Z6 J$ P1 h4 ncal features of mitosis and [3H]thymidine ' N. m% U8 v% J' {# s
incorporation showed that porcine hepatocytes 3 F1 e7 X$ T( Q$ {) l. C* g
proliferated spontaneously in both monolayers 5 z4 t) h) W/ W! b% A
and beads. The immunoisolating properties of ! y9 u- }* y/ B: H, A
the coated alginate beads were checked by * i5 m2 ~4 L" e
incubating entrapped HLA-typed human $ z4 o/ i4 |3 @3 D: x( t' {+ q }
lymphocytes with specific anti-HLA immuno- : k2 B- t4 b6 l& Q
globulin G and complement: no lysis was
: j: a. v( W) r$ x1 p/ zobserved, in contrast to controls (non-
9 g! ~3 J# X' U0 L; x* D3 i% I \entrapped lymphocyteS)o In addition, we have 9 Z) R8 T/ Z6 {' `8 _; f
recently demonstrated that cryopreservation of
% f9 D% ]$ @" V; O, x9 U1 y8 \hepatocytes immobilized in alginate beads did
; o9 t7 K; p# ]4 `( F4 Enot result in marked alterations of liver-specific ' M* k. e- f. h: B: P! k
functions (Guyomard et al., accepted, in
4 n( c1 g8 W3 e: ~press).
& v. q# x+ j9 K2 n1 zAll of the devices described above use hepa- + v; U/ _) @' B9 g: F
tocytes of animal origin, mainly from the pig. / p2 |* I$ G# Y# R
Many initial problems have been solved
3 ]+ I( S- I7 `0 s) D1 `8 \+ ~: {through the use of animal hepatocytes, includ- 8 E* N- v7 B. ?: f( n( X
ing isolation, culture, immobilization, func-
% {5 b8 u6 ]9 i5 m' S7 W- ytional studies, and cryopreservation. The main
: b$ Y4 ?- O8 ~/ Iproblems that remain to be settled are first of
) S" Y9 ]. h M7 f% V2 O) Mimmunological nature and second the risk of U9 z4 X, }: d0 a
xenogenic infections. The immunological pro- ! \8 P' `( v* ?& s0 q |, r& a
blem has been solved in part by the use of , Q2 f2 x& W9 q; p
alginate beads, which prevent the risk of dele-
4 N# m" C( R5 A3 [6 x; zterious effects of human plasma on the cells. 9 u% Z% T1 S# U! T; F
However, both the function and immuno-
! z$ d; z3 G: l! i" N, hgenicity of xenogenic neosynthetized proteins / e2 K# T# B+ S3 v1 J
in human beings remain unknown. Only few 4 B' u8 K+ r: T" B- `
data are available concerning this important
6 j' o, y# g6 F# V$ B# w7 Q' V; W* Sissue. A baboon-to-human liver transplanta-
$ M5 ~2 \0 g% i; H+ Ction was recently performed by T.E. Starzl
4 ?, ~! \4 z; {and colleagues (Starzl et al., 1993). In that
$ F5 s2 q3 F |2 Q$ r# y* Ycase, the function of the baboon proteins 5 H, \& I; ~! J3 r2 O* D6 Q: p
synthetized by the graft seemed to be normal,
- I) M4 S( j* t9 ebut their immunogenicity has not been investi-
7 e' w: `3 i( s; X2 r" M! Agated, due to immunosuppressive drugs and ; z2 d$ J$ m- O7 ]' y( r, ?
the patient's brief survival. The risk for patients 9 z( H. C4 N+ v& Q8 l s K
and public health of xenogenic infections, + A8 Q& j4 [/ z" E- s3 t
particularly retroviral, is a major concern. This 8 O7 S- Q2 h8 m$ W
risk would probably be minimized by using 8 P0 `, _, d, I7 {! J
hepatocytes from pigs, which are phylo-
9 ~: o9 u0 x$ T; J; vgenetically more distant from the human spe-
& F. X' Q# ]- W, j& h9 N8 Ycies than are primates (Chapman et al., 1995).
9 C+ _, O9 l; n4 X4 w j, [ v1 s* R$ ^In order to overcome the problems raised by ( D5 G l8 E" m
the use of xenohepatocytes in EBAL, Sussman - c6 L2 O+ H f+ i
and colleagues have designed another type of 1 d* z& Z& T0 R: |3 w4 U5 _
liver assist device, based on a hollow-fiber
" g1 L8 C* c" m6 t: w/ t. w4 i. Hbioreactor containing cells from the human $ Y: n5 F" t* h! c: Q
C3A cell line (Sussman et al., 1992). This well-
- O8 N3 E2 ?1 X# Q1 D* I, ?differentiated cell line was isolated from a child
( e, y/ M7 {$ n; x* G0 ^& B- {hepatoblastoma. Cells are inoculated in the
5 V. L+ a' s$ K; [4 e* |4 qextracapillary compartment of a bioreactor - Q- ]+ n% W# W6 @, b
and are allowed to grow until confluence for a , `3 U& W$ y- E' C; D
few weeks, after which cells survive within the - h& u2 ?0 H$ K) q
bioreactor for several months in vitro. This
' r- s8 N+ V; q0 Uallows immediate availability for clinical use,
6 p, Y$ r5 U) }+ sat the cost of important culture and storage / s% |0 O) L! O/ ]
units capable of maintaining hundreds of bio- 1 P+ p; `4 U! k- Q! ?& E+ q1 z
reactors for several months. Such an EBAL 329 6 K! ^% b( S/ Y# w4 s8 M( ^% ?
contains a significant mass of cells, and could
( O# a3 a2 `. Wthus potentially represent a very efficient de- & A6 K+ d, e0 p8 ^9 E
vice. A multicentric study is in progress in the ! [( ~8 @, i, r! j8 f% X& c5 k
United States and Europe. Preliminary results , W j+ i2 `: L! Z1 F/ S) g$ F
from 17 patients have been published recently
9 H( B6 R% I0 D3 m, [(Sussman et al., 1994; Ellis et al., 1994), but no ) G5 H F% t# D( M3 G
definitive conclusion can be drawn. The major
1 |% L( ^2 s3 adrawback of this system is the use of C3A , _$ v% G$ K; a' o8 K5 x
neoplastic cells in the EBAL. The risk of tumor 5 I: g2 S+ N1 T) e
graft and/or induction in the treated patients 0 N, @; R4 ]8 b, G* P
has been suggested. Moreover, it is known that
" v$ N( T+ X) a: n9 i3 Y8 othe functional capacities of transformed ) O0 u2 W& Y8 V2 p" M! N0 h: Y4 v6 ?
hepatoblastoma cells are much lower than ( |- B6 @( V5 w6 Y) D1 v/ X |3 ~5 b
those of freshly isolated normal hepatocytes. " y7 o( a1 D$ O9 t
In conclusion, there are many solutions to ) N0 d/ s' k9 z8 I+ ` K0 }
the various problems raised in the use of an
' q3 t* v+ l: h5 Z0 r2 Jextracorporeal bioartificial liver for the treat- / P+ k8 n* K5 K
ment of ALF. Each solution displays advan- ( J( g7 J+ X& T
tages and disadvantages, but the existing 6 V8 E- ?& E5 P9 o
results clearly show that cell-based therapy of
$ w0 [0 X- n' E5 [& QALF is feasible and should be available in the 0 k7 {9 ^3 |0 z. H4 l1 N# {
near future. 3 N r0 f. {) k& J2 C: o4 L
Acknowledgments
- c G3 k: u( z/ [This work was supported by INSERM and by
* q* a; |0 L1 w4 B. \grants from Minist~re de la Recherche
3 c% h# L, @ @. Q0 P4 a+ a(DSPT5-ACC-SV No.14; Biotechnologie) and 0 x" P2 u- E8 w' N5 q. y) X
Fondation de l'Avenir (ET5.144). w' k, k1 Z4 w2 B9 H; w7 X
References
+ E F" f: ~ D4 z/ `0 eArnaout WS, Moscioni AD, Barbour RL, Demetriou AA.
3 }+ B" _$ `2 ^. U2 m7 `. k2 MDevelopment of bioartificial liver; bilirubin conjugation in , B9 v* ^* s" \& Q( h9 W H
Gunn rats. J Surg Res. 1990;48:379-82. # ?% r: R' V! T* T4 A) V/ Z( m
Chapman LE, Folks TM, Salomon DR, Patterson AP, Egger-
3 p! o* o" I( j+ o" uman TE, Noguchi PD. Xenotransplantation and xenogeneic 3 C0 d' j4 e2 V9 d
infections. N Eng J Med. 1995;333:1498-501.
% f4 \6 n. ?8 H& H& S) ]- JChen S, Watanabe FD, Rozga J et al. Clinical experience with a
( [" u4 o4 w+ ebioartificial liver (BAL). Hepatology. 1995;22:203A. 5 V2 g1 P/ G* x' p K' g
Chesn6 C, Guyomard C, Fautrel Aet al. Viability and function
4 O( R% y! _" a9 {8 h. x* \in primary culture of adult hepatocytes from various animal * G1 P$ Q& m. \3 i$ l% |
species and human beings after cryopreservation. Hepatol- 9 p- d9 g6 g& N2 S7 t8 `
ogy. 1993;18:406-14. 3 q& b0 a5 M( [6 g f# @
Demetriou AA, Rozga J, Podesta Let al. Early clinical & i' K6 [; I) E% u2 f4 E
experience with a hybrid bioartificial liver. Stand J Gastro-
3 \" k, G8 w) _* y8 ^6 C; ?# denterol. 1995;30(supplement 208): 111-7.
2 I4 \6 O* I$ I& ~' EEllis A J, Wendon J, Hughes R et al. A controlled trial of the ' h+ \8 ]. n4 g$ M6 m8 c
Hepatix extracorporeal liver assist device (ELAD) in acute c9 w: v! l# q5 ^3 A8 ]
liver failure. Hepatology. 1994;20:140A. ' j, A. u+ |0 ^! t: z) L8 Q
Fr6mond B, Malandain C, Guyomard C, Chesn6 C, Guillouzo
. a. t* X3 J2 R5 x- |' bA, Campion JP. Correction of bilirubin conjugation in the
$ q. ?/ R* Q$ r& ]! T: k1 r# i. S; Y {% IGunn rat using hepatocytes immobilized in alginate gel * b% I% S( [3 a% b- R
beads as an extracorporeal bioartificial liver. Cell Trans- 2 x& N2 }. W# b0 b4 S
plant. 1993;2:453-60. . `8 L) v; ?" C9 r2 m( r+ V1 `* k
Fujioka H, Cramer DV, Yasunaga C et al. Differential patterns
- l# e9 W& h. Fof reaction of human natural antibodies to pig hepatocytes
( Y( u e+ {9 Uand vascular endothelium. Liver Transplant Surg. 1995;1: 4 P6 A, P- K9 }: V" m
85-93. ) m6 O8 L; B6 q& ^. d6 @3 u8 R
Gerlach JC, Encke J, Hole O, Muller C, Courtney JM, Neuhaus , ~- Y) C3 n* A& q- w" Q( e2 h: }
P. Hepatocyte culture between three dimensionally arranged
; t8 E. d+ r5 {% ]5 Y abiomatrix-coated independent artificial capillary systems ' K: j* s7 j* X) w. D! [
and sinusoidal endothelial cell co-culture compartments. 5 C# C8 w) q; D2 p3 y, M4 s/ |4 T% k' a
Int J Artif Organs. 1994;17:301-6. ( Z" g6 X. y- v) c& `6 \
Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant L" c, f4 [, U
hepatic failure: summary of a workshop. Hepatology.
9 f7 I& X3 g- I' [, b% l' a$ w1995;21:240-52.
- t, u' B2 |% j2 SJauregui HO, Mullon CJP, Trenkler D et al. In vivo evaluation " b& s+ q, y" m3 G
of a hollow fiber liver assist device. Hepatology. 1995;21: 9 a6 j& g# s1 v( J0 J8 d: ]$ h2 l
460-9.
$ L% B0 M7 m# t& mMatsumura KN, Guevara GR, Huston H et al. Hybrid bioarti- 2 s2 y4 g* {: [6 X. J! J
ficial liver in hepatic failure: preliminary clinical report.
& x% N) w5 M% b" I: zSurgery. 1987;101:99-103. ) t8 B8 y# \* d8 L) C* J! j
Nyberg SL, Payne WD, Amiot Bet al. Demonstration of
' E6 D; K& ~; n, l5 i' U: F7 r5 Zbiochemical function by extracorporeal xenohepatocytes in : s7 r; W' Q- R3 G
an anhepatic animal model. Transplant Proc. 1993;25:1944-
0 L+ |" d0 j' J9 | ?5. : C- @8 l/ u) w" w* e
O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes
; T2 J, M! U T1 C& @RD, Williams R. Controlled trials of charcoal hemoperfu- # l9 h' O. _! p$ |' E5 [% U
sion and prognostic factors in fulminant hepatic failure. ; x2 ], O* I+ A3 Y8 X$ l) n
Gastroenterology. 1988;94:1192-8.
' X+ D) v4 Y# h7 s4 n; R/ MRozga J, Williams F, Ro MS et al. Development of a bioartifi- ( N+ y1 y, i8 p
cial liver: properties and function of a hollow-fiber module ; ?! b& g* ?! @) M5 [* c
inoculated with liver cells. Hepatology. 1993;17:258~5.
0 s! Z' x* K( A! V$ K# k( USielaffTD, Hu MY, Amiot B, Rollins MD, Rao S, McGuire B.
B( r' g! @& h- IGel-entrapment bioartificial liver therapy in galactosamine . X( Q( q y" p6 t- _( E( Y0 d) _
hepatitis. J Surg Res. 1995;59:179-84.
( x% _% S7 i5 X) [3 FStarzl TE, Fung J, Tzakis Aet al. Baboon-to-human liver
4 l8 ?7 b7 `5 y0 }( Ctransplantation. Lancet. 1993;341:65-71.
9 {; n' [1 C: R3 R g* o' ^Sussman NL, Chong MG, Koussayer T et al. Reversal of 9 d5 ^! _8 G/ A s
fulminant hepatic failure using an extracorporeal liver assist : _ j7 w/ u! _# M# o& V4 O
device. Hepatology. 1992;16:60-5. 0 E& H4 N* {% M" r, H$ X
Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix 8 l5 ^* r) {' M4 i% C1 ^
extracorporeal liver assist device: initial clinical experience.
9 L! M$ X7 T/ F; f# Z% C- YArtif Organs. 1994; 18:390-6.
: a+ X2 n/ L% T2 h9 t1 W1 GTakahaski M, Matsue H, Matsushita Met al. Does a porcine
7 i* E8 j* G2 |3 M v8 ghepatocyte hybrid artificial liver prolong the survival time of
/ R$ B! B p; B+ {anhepatic rabbits? Asaio J. 1992;38:M468-72.
7 e- D2 y% Z/ B) B( NAddress for correspondence." Benjamin Fr6mond, Groupe DRT,
( F1 ~, G( u" S2 x% M ^INSERM, 2 avenue L6on Bernard, 35043 Rennes, France |
-
总评分: 包包 + 5
查看全部评分
|